Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization

Open Access

Peer-reviewed

Research Article

Eva Jager,

Affiliation Institute for Medical BioMathematics, Bene Ataroth, Israel
⨯
Vincent H. J. van der Velden,

Affiliation Department of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
⨯
Jeroen G. te Marvelde,

Affiliation Department of Immunology, Erasmus MC, University Medical Center Rotterdam, The Netherlands
⨯
Roland B. Walter,

Affiliations Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, Division of Hematology, Department of Medicine, University of Washington, Seattle, Washington, United States of America
⨯
Zvia Agur,

Affiliations Institute for Medical BioMathematics, Bene Ataroth, Israel, Optimata, Ltd, Ramat Gan, Israel
⨯
Vladimir Vainstein

* E-mail: vladimir.dr@gmail.com

Affiliation Institute for Medical BioMathematics, Bene Ataroth, Israel
⨯

Reader Comments (0)

Blood
Is the Subject Area "Blood" applicable to this article?

Thanks for your feedback.
Leukemia
Is the Subject Area "Leukemia" applicable to this article?

Thanks for your feedback.
Drug interactions
Is the Subject Area "Drug interactions" applicable to this article?

Thanks for your feedback.
Drug administration
Is the Subject Area "Drug administration" applicable to this article?

Thanks for your feedback.
Drug research and development
Is the Subject Area "Drug research and development" applicable to this article?

Thanks for your feedback.
Chemical dissociation
Is the Subject Area "Chemical dissociation" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Simulation and modeling
Is the Subject Area "Simulation and modeling" applicable to this article?

Thanks for your feedback.